1. Contracts ending soon
  2. National Institutes of Health
  3. NAICS 541714

Research and Development in Biotechnology (except Nanobiotechnology) contracts ending at National Institutes of Health

Department of Health and Human Services

166 contracts of $100,000 or more under NAICS 541714, research and development in biotechnology (except nanobiotechnology), at National Institutes of Health end in the next 18 months, with $1.03B obligated so far. 52 end within six months, so their follow-on may already be in the works.

Ending in 18 months
166 contracts$1.03B obligated so far
Biggest holder
Ppd Development Lp$123M on 4 contracts ending soon
Open notices
NAICS 541714contract opportunities open now
Source
USAspending.govUpdated Nov 17, 2026, 7:37 PM UTC

Contracts ending soon

Soonest end first. Each contract links to its record on USAspending.gov.

ContractObligatedEndsState
Task Order Title: Next Generation GP130/Il-6/STAT3 Inhibitors for the Prevention of Colitis-Associated Colorectal CancerThe Institute for Cancer Research · 75N91022F00002$1,237,620Nov 17, 2026within a monthPA
Niddk: Data Repository ServicesBooz Allen Hamilton Inc · 75N94021F00001$12,174,868Nov 30, 2026within a monthVA
Syphilis Specimen CollectionUniversity of North Carolina at Chapel Hill · 75N93022C00024$3,590,184Nov 30, 2026within a monthNC
Preclinical Models of Infectious DiseasesEurofins Discovery Services North America, LLC · 75N93022F00001$1,924,594Nov 30, 2026within a monthMO
Purchase of a Preventative Maintenances Package From Miltenyi Biotec Inc.Miltenyi Biotec, Inc. · 75N90026P00059$165,900Nov 30, 2026within a monthMD
Daids Monitoring for 1 Phase III Study: A5300B/I2003B (Phoenix)Ppd Development Lp · 75N93026F00001$3,092,829Dec 14, 2026within a monthNC
Time-Restricted Feeding for Pancreatic Cancer PreventionThe Univeristy of Texas M.d. Anderson Cancer Center · 75N91024F00002$551,730Dec 19, 2026in 1 monthTX
Pre-Clinical Models of Infectious Diseases IdiqUniversity of North Carolina at Chapel Hill · 75N93026F00001$194,646Dec 23, 2026in 1 monthNC
Further Development of Ipsc-Based Vaccine for Colon Cancer PreventionThe Univeristy of Texas M.d. Anderson Cancer Center · 75N91023F00001$1,293,012Dec 25, 2026in 1 monthTX
Is to Develop Pan-Influenza Inhibitors Targeting the Pa Endonuclease From the Viral Replication Complex by Demonstrating Pyronaridine As a Viable Single Dose Treatment for Ebola Infection in…Collaborations Pharmaceuticals, Inc. · 75N93025C00039$1,999,195Dec 29, 2026in 1 monthNC
Advanced Development of Multivalent Vaccine Candidates for Filovirus and Lassa FeverAuro Vaccines LLC · 75N93020C00040$10,706,003Dec 31, 2026in 1 monthMD
Contract HHSN272201800010I International Aids Vaccine Initiative Manufacture of Influenza Virus Human Challenge Material for Phase I and II Clinical TestingInternational Aids Vaccine Initiative Inc. · 75N93023F00001$3,625,389Dec 31, 2026in 1 monthNY
Comprehensive in Vitro Antiviral Screening Against Viruses of Pandemic Potential Under Antiviral Program for Pandemics (App)Utah State University · 75N93022F00002$2,022,500Dec 31, 2026in 1 monthID
Production and Distribution of Filarial Research Reagents DataUniversity of Georgia Research Foundation, Inc. · 75N93025F00002$1,392,486Dec 31, 2026in 1 monthGA
Base Award for Task D02 Black Fly Repository SupportUniversity of Georgia Research Foundation, Inc. · 75N93025F00001$355,255Dec 31, 2026in 1 monthGA
To Determine the Antiviral Inhibitory Effect Using Assays Such As Cpe to Determine EC50; Assays Such As Vyr/Pr to Determine EC90, and Cytotoxicity (CC50) of Experimental Compounds Against Viruses…Utah State University · 75N93026F00001$418,905Jan 8, 2027in 1 monthUT
Determination of the in Vitro Activity of Experimental Antifungal Substances Against Fungal Pathogens, Including the Fungal Species Identified in Table 1 Below, As Well As Toxicity of a Subset of…The University of Texas Health Science Center at San Antonio · 75N93026F00001$114,321Jan 13, 2027in 1 monthTX
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (Nichd) Conducts Studies Focusing on Child Health and Human Development and As Such Has Generated and Will…Fisher Bioservices Inc · 75N94025F00001$308,972Jan 21, 2027in 2 monthsMD
Niaid Clinical Site Monitoring (Ncsm)Ppd Development Lp · 75N93024F00001$73,196,564Jan 31, 2027in 2 monthsNC
Autoimmune Diseases Statistical and Clinical Coordinating Center (Adsccc)Rho Federal Systems Division Inc · 75N93022C00003$40,128,916Jan 31, 2027in 2 monthsNC
To Make an Award Under HHS-NIH-Niaid-BAA2018Crestone, Inc. · 75N93019C00056$33,109,378Jan 31, 2027in 2 monthsCO
Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB)Research Triangle Institute · 75N93021C00002$20,112,815Jan 31, 2027in 2 monthsNC
Title: Bladder Cancer Chemoprevention Using the Androgen Receptor Inhibitor ApalutamideUniversity of Oklahoma · 75N91022F00002$1,435,788Feb 4, 2027in 2 monthsOK
Sbir Concept Award for a Novel Delivery Approach to Transform Metastatic Pancreatic Cancer Treatment and PreventionPathcision Medicine, Inc. · 75N91025C00018$299,981Feb 10, 2027in 2 monthsMA
Task A02 - University of Texas Medical Branch (Utmb)University of Texas Medical Branch at Galveston · 75N93024F00006$2,603,774Feb 17, 2027in 3 monthsTX
Nichd: R&D: Repository Services for the Fazst II Task Order Collection: SeverableFisher Bioservices Inc · 75N94026F00001$154,210Feb 22, 2027in 3 monthsMD
Interventional Agents Safety and Pharmacokinetic ServicesEurofins Discovery Services North America, LLC · 75N93026F00001$669,322Feb 24, 2027in 3 monthsMO
Promoting T Cell Recovery After Radiation Injury With Long-Acting Interleukin 7Duke University · 75N93024C00005$3,499,087Feb 28, 2027in 3 monthsNC
Reagents for Immunologic Analysis of Cotton Rat.Sigmovir Biosystems, Inc. · 75N93024C00040$598,871Feb 28, 2027in 3 monthsMD
Task A10 - Test Candidate Therapeutics Against Papillomaviruses in Mouse and Rabbit Models, With the Mouse Model Representing a Screening Model for the More Advanced Studies to Be Conducted in the…Pennsylvania State University · 75N93025F00001$311,680Feb 28, 2027in 3 monthsPA
Diagnostic Development ServicesAdvanced Bioscience Laboratories, Inc. · 75N93026F00002$1,010,033Mar 6, 2027in 3 monthsMD
Performing FDA 510K Enabling Studies for a Diagnostic to Detect Ciprofloxicin Resistance or SusceptabilityMriglobal · 75N93026F00003$1,571,051Mar 10, 2027in 3 monthsMO
Validation of Bioanalytical Assays and Ind- Enabling Glp Pd/Pk Toxicology Studies in Rats and DogsBattelle Memorial Institute · 75N95024F00001$1,553,595Mar 10, 2027in 3 monthsOH
Purchase of Gmp Grade Crispr Base-Editing Guide Rna for Xscid Patients at the Clinical Center. Synthego Holdings LLC (Ambis #2280586)Synthego Holdings LLC · 75N98026P00112$140,000Mar 10, 2027in 3 monthsMD
Nida Center for Genetic Studies. March 14, 2026 - March 13, 2027. N01DA-23-7787. Task Order 75N95026F00001 (TO4). Eo 14271: Dap-Ncap-00000089Infinity Biologix LLC · 75N95026F00001$2,957,934Mar 13, 2027in 3 monthsNJ
The Production of Well Characterized Challenge Material of Bsl-3/4 Viruses.American Type Culture Collection · 75N93022F00001$2,839,794Mar 14, 2027in 3 monthsVA
Targeting the A2B Adenosine Receptor for Immunoprevention of Pancreatic CancerThe Univeristy of Texas M.d. Anderson Cancer Center · 75N91023F00003$1,272,481Mar 14, 2027in 3 monthsTX
NIH Tcf Base Year 1 Task a-1, 03/21/2020-03/20/2021Emory University · 75N93020F00001$20,383,102Mar 20, 2027in 4 monthsGA
Task Area B-2; Pop 09/14/2020-03/20/2023; Dait/Biod Can 8470039; $599,404.00Emory University · 75N93020F00003$599,404Mar 20, 2027in 4 monthsGA
Interventional Agents Chemistry ServicesAapharmasyn LLC · 75N93026F00002$580,843Mar 23, 2027in 4 monthsMI
Non-Glp Dose-Range Finding and Glp Toxicity Studies in Minipigs and in Vitro Drug-Drug Interaction Studies for a Small PeptideBattelle Memorial Institute · 75N95024F00002$2,477,057Mar 25, 2027in 4 monthsMD
Glp Repeat Dose Toxicology Study for a Live-Attenuated Respiratory Virus Vaccine.Lovelace Biomedical Research Institute · 75N98026F00001$339,534Mar 27, 2027in 4 monthsMD
Further Characterization and Validation of Monoclonal Antibodies to Study RespiratoryAmpersand Biosciences LLC · 75N93024C00087$1,084,824Mar 28, 2027in 4 monthsNY
Regulatory Operations Support ServicesTechnical Resources International, Inc. · 75N93023F00001$1,094,796Mar 30, 2027in 4 monthsMD
Niaid/Daids Regulatory Support CenterTechnical Resources International, Inc. · 75N93024F00001$56,583,915Apr 14, 2027in 4 monthsMD
Daids Quality Assurance, Quality Control and Inspection Readiness Support ServicesTechnical Resources International, Inc. · 75N93025F00001$5,807,523Apr 16, 2027in 4 monthsMD
Nichd: R&D: Maternal-Fetal Medicine Units (Mfmu) and the Safe Passage Study (Pass) Task Order: SeverableFisher Bioservices Inc · 75N94025F00005$498,669Apr 27, 2027in 5 monthsMD
Nonclinical Services for the Development of Interventional Agents for Infectious DiseasesSouthern Research Institute · 75N93022F00001$2,354,672Apr 30, 2027in 5 monthsAL
Pcmid Task Order B03 - Evaluation of Antiviral Drug Candidates Against Mpox in NhpsBattelle Memorial Institute · 75N93025F00001$1,250,576Apr 30, 2027in 5 monthsOH
Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers Task Order Title: Sulforaphane for the Prevention of Malignant MesotheliomaThe Institute for Cancer Research · 75N91023F00003$1,199,274May 2, 2027in 5 monthsPA
Nichd: R&D: Maternal and Pediatric Infectious Disease Branch (Mpidb) Task Order: SeverableFisher Bioservices Inc · 75N94025F00007$1,315,085May 13, 2027in 5 monthsMD
Base Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomakers Task Order Title: Vaccines Against Fusobacterium for Fap-and Lynch…The Institute for Cancer Research · 75N91022F00001$2,051,148May 14, 2027in 5 monthsPA
Biosensics LLC:1186749 [24-003492]Biosensics LLC · 75N95024C00010$2,000,000May 19, 2027in 6 monthsMD
Task Areas Two (2), Three (3), Four (4), and Six (6) for the National Institute of Health (NIH) Brain Research Through Advancing Innovative Neurotechnologies (Brain) Initiative Cell Atlas Network…The Broad Institute, Inc · 75N95023F00002$29,616,800May 28, 2027in 6 monthsMA
Unspecified [23-005143]New York Genome Center, Inc. · 75N95023F00002$22,689,037May 28, 2027in 6 monthsNY
Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Targeting the Parp Pathway for the Prevention of Breast CancerThe Univeristy of Texas M.d. Anderson Cancer Center · 75N91022F00001$1,121,090May 31, 2027in 6 monthsTX
Development of Monoclonal Antibodies to Chemokines in the Ferret Model of Respiratory Disease.Ampersand Biosciences LLC · 75N93025C00018$599,987May 31, 2027in 6 monthsNY
Adjuvant Discovery and Down-Selection for Vaccines Against Infectious and Immune-Mediated DiseasesEnepret Incorporated · 75N93025C00020$599,526May 31, 2027in 6 monthsKY
Eo 14398 - Pcmid A17 - Model Development and in Vivo Screening of Antivirals Directed Against Select TogavirusesUniversity of Tennessee · 75N93026F00001$347,823May 31, 2027in 6 monthsTN
This Task Order Is to Provide Regulatory Support for Vaginitis Pcr Assay.Mriglobal · 75N98026F00001$369,210Jun 1, 2027in 6 monthsMO
Eo 14398 - Pcmid A17 - Model Development and in Vivo Screening of Antivirals Directed Against Select TogavirusesColorado State University · 75N93026F00001$197,555Jun 1, 2027in 6 monthsCO
Eo 14398. Myocardial Intramural Remodeling by Transvenous Tether (Mirth) Implant Design Support and Feasibility Prototypes.Resonetics LLC · 75N98026P01701$275,000Jun 29, 2027in 7 monthsMD
Nhlbi Trans-Omics for Precision Medicine (Topmed) Informatics Research Center (Irc) 2026Regents of the University of Michigan · 75N98026F00001$5,617,704Jun 30, 2027in 7 monthsMI
Midos: a Microrna BiodosimeterChromologic LLC · 75N93023C00016$5,519,191Jun 30, 2027in 7 monthsCA
Baa Research Area 001 - Development of Vaccine Candidates for Biodefense and Emerging Infectious DiseasesAnivive Lifesciences Inc · 75N93024C00009$4,889,710Jun 30, 2027in 7 monthsCA
Development of Anticeramide Treatment As a Novel Medical Countermeasure for Acute Effects of Radiation ExposureCeramedix Holding, LLC · 75N93023C00015$4,223,612Jun 30, 2027in 7 monthsNY
The Pharmacological Development of Ipw-5371 Fumarate As a Radiation Medical Countermeasure for the Treatment of Delayed Radiation Lung Injury Under the FDA Animal RuleInnovation Pathways, LLC · 75N93023C00014$3,608,865Jun 30, 2027in 7 monthsCA
Mitigation of Multi-Organ Delayed Effects of Acute Radiation Exposure (Deare) With Ace-Inhibitor LisinoprilThe Medical College of Wisconsin, Inc. · 75N93023C00013$3,275,826Jun 30, 2027in 7 monthsWI
Development of Radiation/Nuclear Medical Countermeasures (Mcms) and Biodosimetry Devices. 7-1/2026 to 6/30/2026. Dap-Ncap-00000073.Ceramedix Holding, LLC · 75N93026C00007$1,500,000Jun 30, 2027in 7 monthsNY
Development of Radiation/Nuclear Medical Countermeasures (Mcms) and Biodosimetry Devices. 7/1/2026 to 6/30/2027. Dap-Ncap-00000073.Micron Biomedical Inc · 75N93026C00009$1,499,999Jun 30, 2027in 7 monthsGA
Development of Radiation/Nuclear Medical Countermeasures (Mcms) and Biodosimetry Devices. 7/1/2026 to 6/30/2027. Dap-Ncap-00000073.Chromologic LLC · 75N93026C00008$1,499,966Jun 30, 2027in 7 monthsCA
Development of Radiation/Nuclear Medical Countermeasures (Mcms) and Biodosimetry Devices. 7/1/26 - 6/30/27. Eo 14271: Dap-Ncap-00000073Asell, LLC · 75N93026C00006$1,492,621Jun 30, 2027in 7 monthsMD
Pcmid C03 - Screening Candidate Countermeasures for Seasonal and High Path Avian Influenza in a Human Lung Microphysiological SystemAmerican Type Culture Collection · 75N93026F00001$855,413Jun 30, 2027in 7 monthsVA
Colorectal Cancer (Crc) Prevention by Urolithin a in Rodent Crc ModelsThe Institute for Cancer Research · 75N91023F00001$1,038,958Jul 9, 2027in 7 monthsPA
Carrrp Task Area aTotal Trials, Inc. · 75N93023F00001$332,178Jul 19, 2027in 8 monthsMD
Screening Candidate Countermeasures for Viral Hemorrhagic Fever Using Liver-Based Organ-on-a-Chip Microphysiological Systems (Mps) in High-Level ContainmentUniversity of Texas Medical Branch at Galveston · 75N93026F00002$1,388,934Jul 26, 2027in 8 monthsTX
Screening Candidate Countermeasures for Viral Encephalitis in Human Central Nervous System and Blood Brain Barrier (Bbb) Microphysiological Systems (Mps)American Type Culture Collection · 75N93026F00002$649,709Jul 26, 2027in 8 monthsVA
Nichd: Service: Repository Services for Dash Biobank: SeverableFisher Bioservices Inc · 75N94026F00002$941,215Jul 30, 2027in 8 monthsMD
Nichd:R&D:Data Coordinating Center for Preparation, Training Activities, Enrollment and Data Collection and Data Analysis of the Span Study:Non-SeverableTechnical Resources International, Inc. · 75N94025F00001$791,681Jul 31, 2027in 8 monthsMD
To Provide Assistance in Protocol Review, Protocol Development and Activities With Past, Present and Future Cctn Activities.University of California, Davis · 75N94020F00001$109,206Jul 31, 2027in 8 monthsCA
To Assist in the Development of New Contraceptive Products by Providing Services Related to Protocol Review, Protocol Development and Activities Associated With Past, Present and Future Cctn…Regents of the University of California, San Francisco, the · 75N94020F00001$104,755Jul 31, 2027in 8 monthsCA
Nimh: Service: Scientific Support Services: Non-SeverableOxford Stemtech Ltd · 75N98026P01200$248,747Aug 5, 2027in 8 monthsMD
Task Order Title: Preventing Lung Adenocarcinoma (Luad) Using Trail Inducing Agent, ONC201 Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate…University of Oklahoma · 75N91022F00003$982,258Aug 7, 2027in 8 monthsOK
Comprehensive and Rapid Response for Niaid Research Programs Hiv and Other Infectious Diseases Clinical Research Support Services (Crss)Ppd Development Lp · 75N93024F00002$26,101,778Aug 14, 2027in 8 monthsNC
Interventional Agents Chemistry ServicesFisher Bioservices Inc · 75N93026F00001$1,066,832Aug 14, 2027in 8 monthsMD
To Provide Scientific Support to the Centers for Research on Structural Biology of Infectious Diseases.Seattle Children's Hospital · 75N93022C00036$26,433,026Aug 31, 2027in 9 monthsWA
To Provide Scientific Support to the Centers for Research on Structural Biology of Infectious Diseases.Northwestern University · 75N93022C00035$25,308,332Aug 31, 2027in 9 monthsIL
Adjuvant Comparison and CharacterizationThe Leland Stanford Junior University · 75N93022C00052$19,155,153Aug 31, 2027in 9 monthsCA
Vesivax TLR7 FormulaMolecular Express, Inc · 75N93024C00017$2,999,352Aug 31, 2027in 9 monthsCA
Validation and Optimization of One-Step Tagging in Human Induced Pluripotent Stem CellsJackson Laboratory · 75N98026P01464$1,673,413Aug 31, 2027in 9 monthsME
Task A28 - Syrian Golden Hamster Model for Testing Medical Countermeasures (Mcm) Against Nipah Virus (Niv)University of Texas Medical Branch at Galveston · 75N93026F00003$1,330,980Aug 31, 2027in 9 monthsTX
Phase II Development of Rapid Molecular Assay for Point of Care Detection of Treponema PallidumTetracore, Inc. · 75N93024C00073$1,488,107Sep 2, 2027in 9 monthsMD
Screening of Investigational Agents Through the Ninds Preclinical Screening Platform for Pain (Pspp)Psychogenics Inc. · 75N95024F00001$36,035,836Sep 5, 2027in 9 monthsNJ
Scientific Management and Support to the National Institute of Mental Health (Nimh) Repository and Genomics Resource (Nrgr)Coriell Institute for Medical Research, Inc. · 75N95025C00007$19,021,976Sep 10, 2027in 9 monthsNJ
Base Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Task Order Title: Colorectal Cancer (Crc) Prevention by Tpst-1495 in Pirc Rat…University of Oklahoma · 75N91023F00001$1,140,397Sep 10, 2027in 9 monthsOK
Issuance of Task Order for the Care, Breeding, and Provison of Spf Macaques. Dap-Ncap-00000188Alpha Genesis Inc · 75N98026F00001$8,092,003Sep 12, 2027in 9 monthsSC
Mouse and Guinea Pig Models for Cytomegalovirus and Herpes Simplex VirusesUniversity of Texas Medical Branch at Galveston · 75N93025F00001$2,343,311Sep 14, 2027in 9 monthsTX
Evaluation of Therapeutics and Vaccines in Mouse Models of Dengue Virus.University of Texas Medical Branch at Galveston · 75N93026F00001$844,795Sep 14, 2027in 9 monthsTX
Niddk: R&D: Ras Mtls Pilot for Nhlbi Bdc and Niddk-Cr: Non-SeverableBooz Allen Hamilton Inc · 75N94026F00001$199,976Sep 14, 2027in 9 monthsVA
Nichd: R&D Services: Repository Services for Legacy Collection Task Order: SeverableFisher Bioservices Inc · 75N94025F00010$1,416,922Sep 15, 2027in 9 monthsMD
FY26 Award. Nida Developmental Studies Biorepository and Analysis Center. September 17, 2026 - September 16, 2027. N01DA-21-5588. Task Order 75N98026F00001 (TO6). Dap-Ncap-00000130.Booz Allen Hamilton Inc · 75N98026F00001$5,359,912Sep 16, 2027in 9 monthsVA
Broad Institute, Inc., the:1157729 [26-003213] 5-Base Sample Prep and Whole Genome Multiomic ProfilingThe Broad Institute, Inc · 75N98026P01702$140,000Sep 16, 2027in 9 monthsMA
Illumina Dragen Gcp Lvl 4 1-Year LicenseIllumina, Inc. · 75N98026P01619$113,004Sep 17, 2027in 10 monthsCA
Fisher CMSFisher Bioservices Inc · 75N93022C00023$29,417,403Sep 20, 2027in 10 monthsMD
Pre-Clinical Models of Infectious DiseasesUtah State University · 75N93026F00002$250,324Sep 20, 2027in 10 monthsUT
Nia - Biologic Kits and Samples - Non-Severable10X Genomics, Inc. · 75N98026P01808$249,990Sep 21, 2027in 10 monthsCA
The Scope of This Contract Will Be to Produce, Maintain, and Distribute Aneuploid Mice With a Primary Emphasis on Models of Human Trisomy for Chromosome 21. SeverableJackson Laboratory · 75N94026C00003$749,999Sep 24, 2027in 10 monthsME
American Type Culture Collection- Task Area EAmerican Type Culture Collection · 75N93023F00001$2,663,890Sep 26, 2027in 10 monthsMD
Task A20 - Interventional Agent Testing Against High Containment VirusesUtah State University · 75N93026F00001$1,235,656Sep 27, 2027in 10 monthsUT
75N94020D00007 Core Function ActivitiesLundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center · 75N94020F00001$261,375Sep 27, 2027in 10 monthsCA
Core Function ActivitiesUniversity of Washington · 75N94020F00001$250,411Sep 27, 2027in 10 monthsWA
Nia: Service: Plasma Metabolon Assay for Baltimore Longitudinal Study of Aging (Blsa).: SeverableMetabolon, Inc. · 75N98026P01908$164,205Sep 27, 2027in 10 monthsMD
Nia - Whole Genome Sequencing - Non-SeverableThe Broad Institute, Inc · 75N98026P01944$215,100Sep 28, 2027in 10 monthsMA
Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (Impac-Tb)Seattle Children's Hospital · 75N93019C00070$90,532,553Sep 29, 2027in 10 monthsWA
Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (Impac-Tb)President and Fellows of Harvard College · 75N93019C00071$59,907,089Sep 29, 2027in 10 monthsMA
To Develop Innovative and Safe Multivalent Anti-Opioid Vaccines That Protect Against Heroin and Fentanyl.University of Montana · 75N93020C00039$25,915,968Sep 29, 2027in 10 monthsMT
To Develop Innovative and Safe Multivalent Anti-Opioid Vaccines That Protect Against Heroin and Fentanyl.Children's Hospital Corporation, the · 75N93020C00038$19,894,862Sep 29, 2027in 10 monthsMA
To Identify Novel Adjuvant Candidates That Can Be Used to Augment the Efficacy of Human Vaccines.University of Montana · 75N93019C00045$18,472,564Sep 29, 2027in 10 monthsMT
Ninds Center for Clinical Trial ResourcesThe Emmes Company, LLC · 75N95022C00041$9,122,780Sep 29, 2027in 10 monthsMD
Development of Saponin Dmlt Adjuvant (Sda)The Administrators of Tulane Educational Fund · 75N93023C00045$6,697,750Sep 29, 2027in 10 monthsLA
Vaccine Adjuvant Discovery Program (Vadp)University of California, San Diego · 75N93024C00022$5,726,546Sep 29, 2027in 10 monthsCA
Vaccine Adjuvant Discovery ProgramUniversity of Montana · 75N93024C00024$5,433,656Sep 29, 2027in 10 monthsMT
Innovations in Functional B Cell Epitope DiscoveryDuke University · 75N93024C00074$4,602,385Sep 29, 2027in 10 monthsNC
Mycobacterium Tuberculosis Proteome-Wide Epitope Discovery and Host Transcriptome-Wide T Cell Phenotyping in High Disease Burden PopulationsThe Translational Genomics Research Institute · 75N93024C00054$4,088,181Sep 29, 2027in 10 monthsAZ
Innovations in Functional B Cell Epitope DiscoveryThe Leland Stanford Junior University · 75N93024C00075$3,743,597Sep 29, 2027in 10 monthsCA
Vaccine Adjuvant Discovery Program (Vadp)The University of Chicago · 75N93024C00023$3,714,524Sep 29, 2027in 10 monthsIL
CD4 and CD8 T Cell Epitopes Recognized in Autoimmune and Autoinflammatory DiseasesUniversity of Massachusetts Medical School · 75N93024C00085$3,420,000Sep 29, 2027in 10 monthsMA
The Identification and Validation of Epitopes Conserved in Viral Pathogen Families With Pandemic PotentialLa Jolla Institute for Immunology · 75N93024C00056$3,205,458Sep 29, 2027in 10 monthsCA
Identification and Characterization of T Cell Epitopes From Bacterial Pathogens Causing PneumoniaLa Jolla Institute for Immunology · 75N93024C00057$3,205,308Sep 29, 2027in 10 monthsCA
Protective T Cell Epitopes and Immune Receptors for Sexually Transmitted InfectionsUniversity of Washington · 75N93024C00055$3,180,911Sep 29, 2027in 10 monthsWA
Kaler to - Viral Gene Therapy for Menkes DiseaseBattelle Memorial Institute · 75N95024F00003$3,109,431Sep 29, 2027in 10 monthsMD
Development of Covalently Bound Hyaluronic Acid As an Adjuvant for Multivalent Lyme Disease VaccineDesign-Zyme LLC · 75N93024C00016$2,999,999Sep 29, 2027in 10 monthsKS
Vaccine Adjuvant Discovery Program (Vadp)Children's Hospital Corporation, the · 75N93024C00020$2,547,484Sep 29, 2027in 10 monthsMA
Therapeutic Testing in Murine Models of Bacterial InfectionPharmacology Discovery Services Taiwan, Ltd. · 75N93026F00003$545,542Sep 29, 2027in 10 monthsNot stated
Regulatory Management Center (Rmc)Ppd Development Lp · 75N93022C00001$20,372,255Oct 31, 2027in 11 monthsNC
The Purpose of This Contract Is to Establish Collection Sites(S) (I.e., the NIH Neurobiobank Brain and Tissue Repository (Nbb)) to Provide Services That Will Actively Acquire, Receive, Process…The Mclean Hospital Corporation · 75N95026C00003$6,965,688Oct 31, 2027in 11 monthsMA
The Purpose of This Contract Is to Establish Collection Sites(S) (I.e., the NIH Neurobiobank Brain and Tissue Repository (Nbb)) to Provide Services That Will Actively Acquire, Receive, Process…University of Maryland, Baltimore · 75N95026C00007$5,965,385Oct 31, 2027in 11 monthsMD
The Purpose of This Contract Is to Establish Collection Sites(S) (I.e., the NIH Neurobiobank Brain and Tissue Repository (Nbb)) to Provide Services That Will Actively Acquire, Receive, Process…University of Pittsburgh - of the Commonwealth System of Higher Education · 75N95026C00006$3,963,642Oct 31, 2027in 11 monthsPA
The Purpose of This Contract Is to Establish Collection Sites(S) (I.e., the NIH Neurobiobank Brain and Tissue Repository (Nbb)) to Provide Services That Will Actively Acquire, Receive, Process…Greater Los Angeles Veterans Research and Education Foundation · 75N95026C00008$3,798,193Oct 31, 2027in 11 monthsCA
The Purpose of This Contract Is to Establish Collection Sites(S) (I.e., the NIH Neurobiobank Brain and Tissue Repository (Nbb)) to Provide Services That Will Actively Acquire, Receive, Process…Icahn School of Medicine at Mount Sinai · 75N95026C00005$3,549,156Oct 31, 2027in 11 monthsNY
The Purpose of This Contract Is to Establish Collection Sites(S) (I.e., the NIH Neurobiobank Brain and Tissue Repository (Nbb)) to Provide Services That Will Actively Acquire, Receive, Process…University of Miami · 75N95026C00004$3,481,912Oct 31, 2027in 11 monthsFL
The Purpose of This Contract Is to Establish Collection Sites(S) (I.e., the NIH Neurobiobank Brain and Tissue Repository (Nbb)) to Provide Services That Will Actively Acquire, Receive, Process…The University of Iowa · 75N95026C00002$2,875,039Oct 31, 2027in 11 monthsIA
Biolincc Program - Task Area aInformation Management Services, Inc. · 75N98027F00001$1,620,000Nov 15, 2027in 11 monthsMD
Nichd:R&D:Central Laboratory for a Phase 2B Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception:Non-SeverableOregon Health & Science University · 75N94025F00002$720,543Dec 31, 2027in 13 monthsOR
Nichd: R&D: a Phase 2B Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception: Non-SeverableBoston Medical Center Corporation · 75N94025F00001$599,807Dec 31, 2027in 13 monthsMA
Nichd: Service: Cctn Lb Phase 2B Clinical Trial: Non-SeverableThe Regents of the University of Colorado · 75N94025F00001$585,325Dec 31, 2027in 13 monthsCO
Nichd: R&D: to Evaluate in Obese and Non-Obese Women the Pharmacokinetics (Pk), Pharmacodynamic (Pd) Effects, Safety, and Contraceptive Efficacy of Levonorgestrel Butanoate (Lb) Formulated As a…Oregon Health & Science University · 75N94025F00001$543,457Dec 31, 2027in 13 monthsOR
Nichd: R&D: a Phase 2B Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception: Non-SeverableThe Trustees of Columbia University in the City of New York · 75N94025F00001$539,573Dec 31, 2027in 13 monthsNY
Nichd: R&D: a Phase 2B Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception: SeverableUniversity of California, Davis · 75N94025F00001$532,750Dec 31, 2027in 13 monthsCA
Nichd: Service: Cctn Lb Phase 2B Clinical Trial: Non-SeverableOld Dominion University · 75N94025F00001$508,827Dec 31, 2027in 13 monthsVA
Nichd: Service: Cctn Lb Phase 2B Clinical Trial: Non-SeverableUniversity of Utah · 75N94025F00001$498,819Dec 31, 2027in 13 monthsUT
Interventional Agents Safety and Pharmacokinetic ServicesSri International · 75N93027F00002$781,955Jan 14, 2028in 13 monthsCA
Therapeutic Testing in Murine Models of Fungal InfectionsThe University of Texas Health Science Center at San Antonio · 75N93026F00001$386,096Jan 26, 2028in 14 monthsTX
Development of Enzyme-Linked Immunosorbent Assays (Elisas) for Ninds NIH Blueprint Neurotherapeutics (Bpn) Biologics ProjectBattelle Memorial Institute · 75N95023F00001$531,194Feb 6, 2028in 14 monthsOH
Nonclinical Services for the Development of Interventional Agents for Infectious DiseasesSri International · 75N93022F00011$4,950,919Mar 13, 2028in 15 monthsCA
Project Title: Low-Dose Erlotinib and Mesalamine for Prevention of Colitis-Associated Colorectal Cancer (Cac)The Univeristy of Texas M.d. Anderson Cancer Center · 75N91025F00001$1,324,125Mar 24, 2028in 16 monthsTX
Base Idiq Title: Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Task Order Title: Further Development of Mitochondria-Targeted…University of Oklahoma · 75N91025F00001$1,234,179Mar 24, 2028in 16 monthsOK
Biologics Idiq Task Order- Non-Glp Toxicity and Toxicokinetic Studies in Rodents and Non-Rodents for a Novel, Subcutaneously-Dosed Modified-Heparin DrugBattelle Memorial Institute · 75N95025F00001$1,028,501Mar 28, 2028in 16 monthsOH
Adjuvant Comparison and CharacterizationUniversity of California Irvine · 75N93022C00054$12,983,474Apr 30, 2028in 17 monthsCA
Adjuvant Comparison and CharacterizationDuke University · 75N93022C00053$8,457,032Apr 30, 2028in 17 monthsNC
1800010I International Aids Vaccine Initiative to V3 Obra 2 Base Task Order Funding Biod Can 8470038 $642,953International Aids Vaccine Initiative Inc. · 75N93019F00131$2,203,474Apr 30, 2028in 17 monthsNY
HHSN272201800010I Iavi Storage of Gmp and Non-Gmp Materials for Niaid Base Award, Can 8470038 for $435,313.50 Can 8040917 for $435,313.50 Total $870,627International Aids Vaccine Initiative Inc. · 75N93021F00001$963,185Apr 30, 2028in 17 monthsNY
Pre-Clinical Models of Infectious DiseasesSigmovir Biosystems, Inc. · 75N93027F00001$609,695May 8, 2028in 17 monthsMD
Manufacture of Influenza Virus Human Challenge Material for Phase 1 and 2.Idt Biologika Gmbh · 75N93023F00001$4,154,750May 14, 2028in 17 monthsNot stated
1800010I International Aids Vaccine Initiative Manufacture of Human Flu Challenge MaterialInternational Aids Vaccine Initiative Inc. · 75N93018F00002$4,151,337May 14, 2028in 17 monthsNY
1800009I Advanced Bioscience Laboratories, Inc.; to V4 Pipb 1 Base Task Order Funding; Iid Can 8470036 $173,773Advanced Bioscience Laboratories, Inc. · 75N93019F00131$534,190May 14, 2028in 17 monthsMD

End dates are the current period of performance; options not yet exercised can extend them. An ending contract may be competed again, extended, or moved to another vehicle. BPA calls and orders shorter than six months are left out. Department of Defense contracts appear on USAspending.gov about 90 days after award.

Get new notices under NAICS 541714

New contract opportunities under NAICS 541714, research and development in biotechnology (except nanobiotechnology), the morning they appear. Free while in beta.

Free. We use your email only for these alerts and never share it. Privacy